Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabrazyme Extension Study in Fabry Disease
NCT00081497Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2004
- Primary completion
- Sep 2005
- Modality
- Replacement Enzymes
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Difference in Inverse Serum Creatinine Within Patients' Slopes Between the Placebo AGAL-008-00 and Fabrazyme AGAL02503 Periods at 18 months. Started Jan 2004; status: completed.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00081497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081497.